← All trials
NCT05155254
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Apr 30, 2025
- Completion date
- May 31, 2027
- First posted
- Dec 13, 2021
- Last posted
- Dec 13, 2021
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- IO BiotechLead sponsor
- MerckCollaborator
- Syneos HealthCollaborator
- Almac Clinical Services LLCCollaborator
- University of CopenhagenOverall official - principal investigator
- Klifo A/SCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.